PeptiPharma

PeptiPharma is a Japanese biotechnology company specializing in the discovery and development of macrocyclic peptide-based therapeutics and diagnostics. Utilizing a proprietary discovery platform, the company identifies high-affinity peptides that can be conjugated to various payloads, including cytotoxic drugs and radioisotopes. PeptiPharma's primary focus is on oncology, with a pipeline led by PP-001, a candidate targeting integrin receptors for both cancer imaging and therapy. The company aims to address unmet medical needs by providing highly targeted treatments that offer improved safety profiles over conventional therapies. Headquartered in the Tonomachi King SkyFront innovation hub, PeptiPharma collaborates with leading academic institutions to advance its peptide-drug conjugate (PDC) technology.